Health Care [ 4/12 ] | Life Sciences Tools & Services [ 51/74 ]
NASDAQ | Common Stock
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems.
The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases.
It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides.
In addition, the company provides Revio, Vega, Sequel, Sequel II, and Sequel IIe instruments which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits.
It serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies.
The company markets its products through a sales force and distribution partners in Australia, certain parts of Asia, Europe, the Middle East, Africa, Central America, and South America.
The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005.
Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 13, 25 | -0.20 Increased by +35.48% | -0.17 Decreased by -15.47% |
| Nov 7, 24 | -0.22 Increased by +15.38% | -0.22 |
| Aug 7, 24 | -0.64 Decreased by -128.57% | -0.23 Decreased by -178.26% |
| May 9, 24 | -0.29 Increased by +19.44% | -0.28 Decreased by -3.57% |
| Feb 15, 24 | -0.31 Increased by +16.22% | -0.29 Decreased by -6.90% |
| Oct 30, 23 | -0.26 Increased by +23.53% | -0.33 Increased by +21.21% |
| Aug 2, 23 | -0.28 Increased by +12.50% | -0.32 Increased by +12.50% |
| May 2, 23 | -0.36 Increased by +2.70% | -0.33 Decreased by -9.09% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 39.22 M Decreased by -32.79% | 2.37 M Increased by +102.89% | Increased by +6.04% Increased by +104.30% |
| Sep 30, 24 | 39.97 M Decreased by -28.23% | -60.73 M Increased by +9.19% | Decreased by -151.94% Decreased by -26.54% |
| Jun 30, 24 | 36.01 M Decreased by -24.30% | -173.32 M Decreased by -148.19% | Decreased by -481.27% Decreased by -227.86% |
| Mar 31, 24 | 38.81 M Decreased by -0.23% | -78.18 M Increased by +3.66% | Decreased by -201.44% Increased by +3.44% |
| Dec 31, 23 | 58.36 M Increased by +113.35% | -82.02 M Decreased by -2.73% | Decreased by -140.55% Increased by +51.85% |
| Sep 30, 23 | 55.69 M Increased by +72.36% | -66.87 M Increased by +20.02% | Decreased by -120.07% Increased by +53.59% |
| Jun 30, 23 | 47.57 M Increased by +34.13% | -69.83 M Increased by +2.19% | Decreased by -146.79% Increased by +27.08% |
| Mar 31, 23 | 38.90 M Increased by +17.26% | -81.15 M Increased by +3.87% | Decreased by -208.61% Increased by +18.02% |